As of 2026-04-02, the Relative Valuation of Esperion Therapeutics Inc (ESPR) is (1.52) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.74 USD, the upside of Esperion Therapeutics Inc based on Relative Valuation is -155.6%.
The range of the Relative Valuation is (1.32) - (1.75) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.9x - 19.9x | 18.1x |
| Forward P/E multiples | 14.1x - 19.9x | 16.4x |
| Fair Price | (1.32) - (1.75) | (1.52) |
| Upside | -148.0% - -164.0% | -155.6% |
| Date | P/E |
| 2026-04-01 | -29.61 |
| 2026-03-31 | -31.02 |
| 2026-03-30 | -29.78 |
| 2026-03-27 | -31.02 |
| 2026-03-26 | -32.27 |
| 2026-03-25 | -31.25 |
| 2026-03-24 | -29.66 |
| 2026-03-23 | -29.66 |
| 2026-03-20 | -28.87 |
| 2026-03-19 | -29.44 |
| 2026-03-18 | -28.36 |
| 2026-03-17 | -30.68 |
| 2026-03-16 | -30.46 |
| 2026-03-13 | -27.63 |
| 2026-03-12 | -27.97 |
| 2026-03-11 | -29.32 |
| 2026-03-10 | -30.57 |
| 2026-03-09 | -34.42 |
| 2026-03-06 | -30.80 |
| 2026-03-05 | -31.36 |
| 2026-03-04 | -32.95 |
| 2026-03-03 | -32.95 |
| 2026-03-02 | -37.02 |
| 2026-02-27 | -37.93 |
| 2026-02-26 | -38.04 |
| 2026-02-25 | -37.70 |
| 2026-02-24 | -37.36 |
| 2026-02-23 | -37.82 |
| 2026-02-20 | -39.40 |
| 2026-02-19 | -39.85 |
| 2026-02-18 | -40.42 |
| 2026-02-17 | -40.19 |
| 2026-02-13 | -38.84 |
| 2026-02-12 | -38.50 |
| 2026-02-11 | -39.17 |
| 2026-02-10 | -38.38 |
| 2026-02-09 | -37.59 |
| 2026-02-06 | -38.50 |
| 2026-02-05 | -36.00 |
| 2026-02-04 | -38.72 |
| 2026-02-03 | -39.74 |
| 2026-02-02 | -39.63 |
| 2026-01-30 | -38.38 |
| 2026-01-29 | -40.19 |
| 2026-01-28 | -39.17 |
| 2026-01-27 | -38.72 |
| 2026-01-26 | -37.82 |
| 2026-01-23 | -35.55 |
| 2026-01-22 | -35.89 |
| 2026-01-21 | -33.74 |